

14 Dec 2023 | News

Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics

Latest China Biopharma Moves Discussed

by Brian Yang

Chengdu-based Biokin has just signed a \$8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.

Chinese antibody-drug conjugate developers are making further inroads in global biotech dealmaking, with Chengdu-based <u>Biokine Therapeutics Ltd.</u>'s US subsidiary recently inking a megadeal with <u>Bristol Myers Squibb Company</u> worth up to \$8.4bn in total.

On 5 December, Hong Kong-listed *WuXi Biologics* saw a single-day share price plunge of over 23%, following a business update that revealed a broad set of challenges facing the overall Chinese biotech sector. What are the reasons, what will the impact be on the Chinese biotech sector as a whole and what is the outlook like for WuXi in 2024?

In other developments, Brian and Dexter look at why *Pfizer Inc.* decided to divest commercial rights to its most popular vaccine in China, Prevenar 13, to Shanghai Pharma subsidiary Ke Yuan, and what this might mean for multinational vaccine manufacturers operating in China.

Finally, BlissBio recently disclosed Phase I data for its ADC BB-1707 - what are the key takeaways?



XXXXXXXXXXXXXX

(Also see "BMS Bets \$8.4bn On Biokin's Bispecific ADC" - Scrip, 12 Dec, 2023.)

(Also see "Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges" - Scrip, 6 Dec, 2023.)

(Also see "*Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction*" - Scrip, 28 Nov, 2023.)

(Also see "*New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer*" - Scrip, 11 Dec, 2023.)

Click here to explore this interactive content online